Literature DB >> 16778101

Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma.

Hiroshi Okumura1, Shoji Natsugoe, Naoya Yokomakura, Yoshiaki Kita, Masataka Matsumoto, Yasuto Uchikado, Tetsuro Setoyama, Tetsuhiro Owaki, Sumiya Ishigami, Takashi Aikou.   

Abstract

PURPOSE: The p53 gene and its family are important factors for carcinogenesis, prognosis, and chemoresistance in esophageal squamous cell carcinoma. A recently identified ribonucleotide reductase, p53R2, is regulated by p53 for supplying nucleotides to repair damaged DNA. In the present study, we analyzed the expression and clinicopathologic significance of p53 and p53R2 in esophageal squamous cell carcinoma. EXPERIMENTAL
DESIGN: We immunohistochemically investigated the relationship between p53 and p53R2 expressions in surgical specimens of primary tumors in 222 patients with esophageal squamous cell carcinoma.
RESULTS: The positive expression rate of p53 was 47.1% and that of p53R2 was 61.7%. Positive p53R2 expression was significantly correlated with depth of invasion, lymph node metastasis, stage, and poor prognosis. In the p53-negative group, the 5-year survival rate was better in patients with negative p53R2 expression than in those with positive p53R2 expression. Multivariate analysis indicated that the negative expression of both p53 and p53R2 was an independent prognostic factor along with tumor depth nodal metastasis and stage.
CONCLUSIONS: We showed that positive p53R2 expression was related to tumor development and that alteration of p53R2 expression in p53-negative tumors was closely related to prognosis. Evaluation of the expressions of p53 and p53R2 proteins should be useful for determining the tumor properties, including prognosis, in patients with esophageal squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778101     DOI: 10.1158/1078-0432.CCR-05-2416

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  22 in total

1.  Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer.

Authors:  Xiyong Liu; Lily Lai; Xiaochen Wang; Lijun Xue; Sofia Leora; Jun Wu; Shuya Hu; Keqiang Zhang; Mei-Ling Kuo; Lun Zhou; Hang Zhang; Yafan Wang; Yan Wang; Bingsen Zhou; Rebecca A Nelson; Shu Zheng; Suzhan Zhang; Peiguo Chu; Yun Yen
Journal:  Cancer Res       Date:  2011-03-17       Impact factor: 12.701

2.  E2F1 regulates p53R2 gene expression in p53-deficient cells.

Authors:  Jun-Juan Qi; Ling Liu; Ji-Xiang Cao; Guo-Shun An; Shu-Yan Li; Gang Li; Hong-Ti Jia; Ju-Hua Ni
Journal:  Mol Cell Biochem       Date:  2014-10-14       Impact factor: 3.396

3.  Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach.

Authors:  James J Farrell; Jennifer Moughan; Jonathan L Wong; William F Regine; Paul Schaefer; Al B Benson; John S Macdonald; Xiyong Liu; Yun Yen; Raymond Lai; Zhong Zheng; Gerold Bepler; Chandan Guha; Hany Elsaleh
Journal:  Pancreas       Date:  2016-11       Impact factor: 3.327

4.  p53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer.

Authors:  Nan-Yung Hsu; Jeng-Yuan Wu; Xiyong Liu; Yun Yen; Chih-Yi Chen; Ming-Chih Chou; Huei Lee; Ya-Wen Cheng
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

Review 5.  Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy.

Authors:  Hiroshi Okumura; Yasuto Uchikado; Tetsuro Setoyama; Masataka Matsumoto; Tetsuhiro Owaki; Sumiya Ishigami; Shoji Natsugoe
Journal:  Surg Today       Date:  2013-04-19       Impact factor: 2.549

6.  p53R2 overexpression in cervical cancer promotes AKT signaling and EMT, and is correlated with tumor progression, metastasis and poor prognosis.

Authors:  Chao Jiang; Rui Xu; Xiao-Xing Li; Yan-Yan Wang; Wen-Qian Liang; Ju-Deng Zeng; Shan-Shan Zhang; Xiao-Yi Xu; Yang Yang; Mei-Yin Zhang; Hui-Yun Wang; X F Steven Zheng
Journal:  Cell Cycle       Date:  2017-08-25       Impact factor: 4.534

7.  Investigation of the association of hRRM1 and p53R2 gene polymorphisms in head and neck squamous cell carcinomas.

Authors:  Kadir Serkan Orhan; Ender Coskunpinar; Deniz Kanliada; Yasemin Musteri Oltulu; Bora Basaran; Mehmet Celik; Bedia Cakmakoglu; Kemal Deger
Journal:  Med Oncol       Date:  2014-05-27       Impact factor: 3.064

Review 8.  Nucleotide metabolism, oncogene-induced senescence and cancer.

Authors:  Katherine M Aird; Rugang Zhang
Journal:  Cancer Lett       Date:  2014-01-29       Impact factor: 8.679

9.  DGCR8/ZFAT-AS1 Promotes CDX2 Transcription in a PRC2 Complex-Dependent Manner to Facilitate the Malignant Biological Behavior of Glioma Cells.

Authors:  Fangfang Zhang; Xuelei Ruan; Jun Ma; Xiaobai Liu; Jian Zheng; Yunhui Liu; Libo Liu; Shuyuan Shen; Lianqi Shao; Di Wang; Chunqing Yang; Heng Cai; Zhen Li; Ziyi Feng; Yixue Xue
Journal:  Mol Ther       Date:  2019-11-20       Impact factor: 11.454

10.  p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest.

Authors:  Keqiang Zhang; Jun Wu; Xiwei Wu; Xiaochen Wang; Yan Wang; Ning Zhou; Mei-ling Kuo; Xiyong Liu; Bingsen Zhou; Lufen Chang; David Ann; Yun Yen
Journal:  Mol Cancer Ther       Date:  2011-01-07       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.